0
Therapeutic Areas
0
Core Products
00000
+
hospitals
000
+
sales representatives
00
Chinese provinces
00000
+
pharmacies
About life and health, professionalism is the fundamental principle for our career.
Excellence runs through every minute of our work.
Responsibility is our attitude towards each task.
With our belief and mission, we will never give up.

About life and health, professionalism is the fundamental principle for our career.

Excellence runs through every minute of our work.

Responsibility is our attitude towards each task.

With our belief and mission, we will never give up.

From very first product to the establishment of a diversified product portfolio covering areas of anti-infectives, cardiovascular, and respiratory, every achievement we gained demonstrates our commitment to life, patients and society by fulfilling the large unmet medical needs.

· EDDING was established.

· We have marketed and sold Zinacef in China on an exclusive basis. Zinacef is an originator branded cefuroxime product.

· We in-licensed Vascepa® from Amarin in 2015 for development and commercialization. Icosapent Ethyl (the generic name of Vascepa) is a transformative drug candidate for reducing CV events and is the first and only drug approved by the FDA as an adjunct to maximally tolerated statin therapy for reducing persistent CV risk in certain high-risk patients according to Frost & Sullivan.

· We in-licensed ERC 301 and ERC 302 together with a proprietary inhaler for drug administration in December 2015 for development, manufacture and commercialization. Both ERC 301 and ERC 302 are high-end generic drugs, the inhalers for which are especially difficult to imitate.

· We have marketed Fortum in China on an exclusive basis in 2016 . Fortum (ceftazidime for injection) is an originator branded anti-infective drug.

· We have marketed and sold Vancocin® and Ceclor® in China on an exclusive basis in 2017. Vancocin is the originator branded product of  of vancomycin.It is the only first-line drug among major therapies included in the NRDL for the treatment of MRSA infections, according to the Frost & Sullivan Report.


· We have marketed Recormon in China on an exclusive basis since 2018. Recormon (recombinant human erythropoietin β injection (CHO cell)) is used for the treatment of cardio-renal-anemia (CRA) syndrome.

· We acquired the products rights for Vancocin® in mainland China and Italy and for Ceclor® in China,and other relevant assets, to become one of the few domestics pharmaceutical companies in China that possess world-class quality management, manufacturing and global supply chain management capabilities.

· We reached an agreement to license-in lusutrombopag, a thrombopoietin receptor agonist (brand name in Japan: MULPLETA®) in China. Mulpleta® is an innovative thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of TCP in certain patients.  Mulpleta® have received approval from the Japan, the U.S. and the EU. 

· We have marketed and sold FLIXOTIDE®(Fluticasone Propionate Nebulizer Suspension) in China on an exclusive basis since 2019. It is the latest-generation and best-in-class ICS nebulizer indicated for the treatment of asthma. FLIXOTIDE® was launched in China in March 2018.

· We in-licensed EDP125 for development and commercialization. EDP 125 is an innovative selective norepinephrine reuptake inhibitor (SNRI) used to treat ADHD.

· We acquired the respiratory product rights in mainland China for FPN (Fluticasone Propionate Nebulizer Suspension) in 2020,as well as the manufacturing technologies, which will enable us to manufacture FPN on our own manufacturing site.

· We conducted the Phase III clinical trial in China for the treatment of severe HTG for Vascepa and submitted NDA to the NMPA in December 2020.


· The NMPA accepted for review the NDA for Vascepa® in February.

· Phase III clinical trail of Mulpleta conducted by Edding in Mainland China achieved positive results;The new drug application (NDA) in Mainland China is currently under review by the Chinese National Medical Products Administration (NMPA).

· We received the IND approval for a Phase III clinical trial in China for EDP 125 indicated for the treatment of ADHD in children and adolescents.

· Receives Approval of Vascepa® to Reduce Cardiovascular Risk in Hong Kong,China.

Unit 122-129, Building A3 No.700, Wanrong Road,Shanghai

publication@eddingpharm.com

沪ICP备2021007464号

Copyright © 2019 亿腾医药 版权所有

药监局备案号: (沪) -非经营性-2021-0038